Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc
- PMID: 1419902
Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc
Abstract
The N-myc oncogene has been implicated in the pathogenesis of a number of human tumors, including childhood neuroblastoma and adult small cell lung cancer. We have isolated and characterized complementary DNA clones derived from a transcription unit, N-cym, located on the opposite DNA strand to N-myc, with extensive overlap existing between the 5' ends of the two transcription units. The N-cym gene, which can encode a 109-amino acid protein, is expressed during fetal development, as well as in tumor cell lines containing amplified N-myc loci, where it is expressed at very high levels. Although other examples of overlapping, opposite-strand eukaryotic genes exist, N-myc and N-cym are unique in that they appear to be coregulated in tumor cell lines under basal growth conditions and in response to the differentiating agent retinoic acid. This coregulation suggests that their protein products may be functionally interrelated during normal development and oncogenesis.
Similar articles
-
Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.Cancer Res. 1994 Apr 15;54(8):2251-5. Cancer Res. 1994. PMID: 8174135
-
N-myc regulation of type I insulin-like growth factor receptor in a human neuroblastoma cell line.Cancer Res. 1999 Jun 15;59(12):2898-902. Cancer Res. 1999. PMID: 10383152
-
Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma.Cancer Res. 1994 Oct 1;54(19):5036-40. Cancer Res. 1994. PMID: 7923112
-
In vivo regulation of single copy and amplified N-myc in human neuroblastoma cells.Oncogene. 1997 Jul 17;15(3):303-15. doi: 10.1038/sj.onc.1201195. Oncogene. 1997. PMID: 9233765
-
Control of c-myc regulation in normal and neoplastic cells.Adv Cancer Res. 1991;56:1-48. doi: 10.1016/s0065-230x(08)60476-5. Adv Cancer Res. 1991. PMID: 2028839 Review. No abstract available.
Cited by
-
MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment.Cancers (Basel). 2022 Sep 12;14(18):4421. doi: 10.3390/cancers14184421. Cancers (Basel). 2022. PMID: 36139583 Free PMC article. Review.
-
Emerging roles of Myc in stem cell biology and novel tumor therapies.J Exp Clin Cancer Res. 2018 Jul 27;37(1):173. doi: 10.1186/s13046-018-0835-y. J Exp Clin Cancer Res. 2018. PMID: 30053872 Free PMC article. Review.
-
CD47-Dependent Regulation of Immune Checkpoint Gene Expression and MYCN mRNA Splicing in Murine CD8 and Jurkat T Cells.Int J Mol Sci. 2023 Jan 30;24(3):2612. doi: 10.3390/ijms24032612. Int J Mol Sci. 2023. PMID: 36768931 Free PMC article.
-
NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas.PLoS Genet. 2014 Jan;10(1):e1003996. doi: 10.1371/journal.pgen.1003996. Epub 2014 Jan 2. PLoS Genet. 2014. PMID: 24391509 Free PMC article.
-
A genome-wide screen for beta-catenin binding sites identifies a downstream enhancer element that controls c-Myc gene expression.Mol Cell Biol. 2008 Dec;28(24):7368-79. doi: 10.1128/MCB.00744-08. Epub 2008 Oct 13. Mol Cell Biol. 2008. PMID: 18852287 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
- Actions
LinkOut - more resources
Molecular Biology Databases